Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01539993
NCT01539993
Completed
Not Applicable

Prospective Analysis of Liver Cancer Treatment and Interventions

Emory University1 site in 1 country400 target enrollmentNovember 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLiver Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Liver Cancer
Sponsor
Emory University
Enrollment
400
Locations
1
Primary Endpoint
Assess efficacy of percutaneous and transarterial treatments for liver cancer.
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
January 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hyun Kevin Kim

MD FSIR, Director of Interventional Radiology and Image-Guided Medicine.

Emory University

Eligibility Criteria

Inclusion Criteria

  • •Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion Criteria

  • •Severe liver disfunction
  • •Active uncontrolled infection
  • •Significant underlying medical of physical illness

Outcomes

Primary Outcomes

Assess efficacy of percutaneous and transarterial treatments for liver cancer.

Time Frame: 1 month

QOL questionnaire will be collected during follow up visit.

Secondary Outcomes

  • long term follow up(3 months, 6 months 1year)

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Prospective Validation of Liver Cancer Risk Computation (LIRIC) ModelsPredictive Cancer Model
NCT06140823Beth Israel Deaconess Medical Center6,000,000
Recruiting
Not Applicable
Liver Cancer and Immunotherapy in the Liquid Biopsy EraHepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaImmune Checkpoint InhibitorLiquid Biopsy
NCT05810402University Hospital, Montpellier60
Recruiting
Not Applicable
Evaluation of Patients With Liver DiseaseHepatitis DHepatitis CHepatitis BLiver Disease
NCT00001971National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)8,050
Active, not recruiting
Not Applicable
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver CirrhosisLiver and Intrahepatic Bile Duct Carcinoma
NCT04785534M.D. Anderson Cancer Center1,000
Recruiting
Not Applicable
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related TherapiesHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
NCT05108519M.D. Anderson Cancer Center170